ppharmПедиатрическая фармакологияPediatric pharmacology1727-57762500-3089Издательство «ПедиатрЪ»10.15690/pf.v11i1.905ppharm-150Research ArticleКЛИНИЧЕСКИЙ СЛУЧАЙCASE REPORTКЛИНИЧЕСКИЙ СЛУЧАЙ ПРИМЕНЕНИЯ ТОЦИЛИЗУМАБА У ПАЦИЕНТКИ С СИСТЕМНЫМ ЮВЕНИЛЬНЫМ ИДИОПАТИЧЕСКИМ АРТРИТОМCLINICAL CASE OF TOCILIZUMAB USE IN A PATIENT WITH SYSTEMIC JUVENILE IDIOPATHIC ARTHRITISЛомакинаО. Л.LomakinaO. L.

аспирант ревматологического отделения Научного центра здоровья детей

graduate student of the rheumatology department of Scientific Center of Children's Health

lomakolga@mail.ruАлексееваЕ. И.AlexeyevaE. I.ДенисоваР. В.DenisovaR. V.СлепцоваТ. В.SleptsovaT. V.ФетисоваА. Н.FetisovaA. N.Научный центр здоровья детей, МоскваРоссияScientific Center of Children's HealthRussian FederationНаучный центр здоровья детей РАМН, Москва, Российская Федерация Первый Московский государственный медицинский университет им. И.М. Сеченова, Российская ФедерацияРоссияScientific Center of Children’s Health, Moscow, Russian Federation First Sechenov Moscow State Medical University, Russian FederationRussian FederationНаучный центр здоровья детей РАМН, Москва, Российская ФедерацияРоссияScientific Center of Children’s Health, Moscow, Russian FederationRussian Federation201415022014111Педиатрическая фармакология9396Copyright © Ломакина О.Л., Алексеева Е.И., Денисова Р.В., Слепцова Т.В., Фетисова А.Н., 20142014Ломакина О.Л., Алексеева Е.И., Денисова Р.В., Слепцова Т.В., Фетисова А.Н.Lomakina O.L., Alexeyeva E.I., Denisova R.V., Sleptsova T.V., Fetisova A.N.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.pedpharma.ru/jour/article/view/150

В статье приведен случай успешного применения препарата моноклональных антител к рецепторам интерлейкина 6(тоцилизумаб) при тяжелом системном варианте ювенильного идиопатического артрита. Лечение тоцилизумабомв короткие сроки обеспечило снижение клинических и лабораторных показателей активности болезни, повышениефизикальной активности ребенка, развитие ремиссии системного ювенильного идиопатического артрита, позволилоизбежать назначения глюкокортикоидов per os.

детисистемный ювенильный идиопатический артриттоцилизумабchildrensystemic juvenile idiopathic arthritistocilizumabReferencesCassidy J. T., Petty R. E., Laxer R. M., Lindsley C. B. Textbook of pediatric rheumatology. 6th ed. Saunders Elsevier, Philadelphia. 2011. 794 р.Cassidy J. T., Petty R. E., Laxer R. M., Lindsley C. B. Textbook of pediatric rheumatology. 6th ed. Saunders Elsevier, Philadelphia, 2011. 794 р.Алексеева Е. И., Валиева С. И., Бзарова Т. М. Эффективность и безопасность повторных курсов лечения ритуксимабом тяжелого рефрактерного ювенильного ревматоидного артрита. Вопросы современной педиатрии. 2009; 8 (5): 14–25.Alexeeva E.I., Valieva S.I., Bzarova T.M. Efficacy and safety of refresher rituximab treatment courses of refractory juvenile idiopathic arthritis. Voprosy sovremennoi pediatrii = Current pediatrics. 2009; 8 (5): 14–25.Бзарова Т. М., Алексеева Е. И., Петеркова В. А. Роль факторов болезни и факторов противоревматической терапии в развитии низкорослости у детей, страдающих ювенильным ревматоидным артритом. Вопросы современной педиатрии. 2006; 5 (5): 13–18.Bzarova T.M., Alexeeva E.I., Peterkova V.A. Role of disease and antirheumatic therapy factors in dwarfism development in children with juvenile idiopathic arthritis. Voprosy sovremennoi pediatrii = Current pediatrics. 2006; 5 (5): 13–18.Kelly A., Ramanan A. V. Recognition and management of macrophage activation syndrome in juvenile arthritis. Curr Opin Rheumatol. 2007; 19: 477–81.Kelly A., Ramanan A. V. Recognition and management of macrophage activation syndrome in juvenile arthritis. Curr. Opin. Rheumatol. 2007; 19: 477–81.Cortis E., Insalaco A. Macrophage activation syndrome in juvenile idiopathic arthritis. Acta Paediatr Suppl. 2006; 95: 38–41.Cortis E., Insalaco A. Macrophage activation syndrome in juvenile idiopathic arthritis. Acta Paediatr Suppl. 2006; 95: 38–41.Rothwell N. J., Busbridge N. J., Lefeuvre R. A., Hardwick A. J. Interleukin-6 is a centrally acting endogenous pyrogen in the rat. Can J Physiol Pharmacol. 1991; 69: 1465–1469.Rothwell N. J., Busbridge N. J., Lefeuvre R. A., Hardwick A. J. Interleukin-6 is a centrally acting endogenous pyrogen in the rat. Can. J. Physiol. Pharmacol. 1991; 69: 1465–1469.Castell J. V., Gomez-Lechon M. J., David M. et al. Recombinant human interleukin-6 (IL-6/BSF-2/HSF) regulates the synthesis of acute phase proteins in human hepatocytes. FEBS Lett. 1988; 232: 347–350.Castell J. V., Gomez-Lechon M. J., David M. et al. Recombinant human interleukin-6 (IL-6/BSF-2/HSF) regulates the synthesis of acute phase proteins in human hepatocytes. FEBS Lett. 1988; 232: 347–350.Nemeth E., Rivera S., Gabayan V. et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest. 2004; 113: 1271–1276.Nemeth E., Rivera S., Gabayan V. et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J. Clin. Invest. 2004; 113: 1271–1276.Ikebuchi K., Wong G. G., Clark S. C., Ihle J. N., Hirai Y., Ogawa M. Interleukin-6 enhancement of interleukin-3-dependent proliferation of multipotential hemopoietic progenitors. Proc Natl Acad Sci USA. 1987; 84: 9035–9039.Ikebuchi K., Wong G. G., Clark S. C., Ihle J. N., Hirai Y., Ogawa M. Interleukin-6 enhancement of interleukin-3-dependent proliferationof multipotential hemopoietic progenitors. Proc. Natl. Acad. Sci USA. 1987; 84: 9035–9039.Kimura H., Ishibashi T., Uchida T., Maruyama Y., Friese P., Burstein S. A. Interleukin-6 is a differentiation factor for human megakaryocytes in vitro. Eur J Immunol. 1990; 20: 1927–1931.Kimura H., Ishibashi T., Uchida T., Maruyama Y., Friese P.,Burstein S. A. Interleukin-6 is a differentiation factor for human megakaryocytes in vitro. Eur. J. Immunol. 1990; 20: 1927–1931.Tsigos C., Papankolaou D. A., Defensor R., Mitsiadis C. S., Kyrou I., Chrousos G. P. Dose-effects of recombinant human interleukin-6 on pituitary hormone secretion and energy expenditure. Neuroendocrinology. 1997; 66: 54–62.Tsigos C., Papankolaou D. A., Defensor R., Mitsiadis C. S., Kyrou I., Chrousos G. P. Dose-effects of recombinant human interleukin-6 on pituitary hormone secretion and energy expenditure. Neuroendocrinology. 1997; 66: 54–62.Heliovaara M. K., Teppo A. M., Karonen S. L., Tuominen J. A., Ebeling P. Plasma IL-6 concentration is inversely related to insulin sensitivity, and acute phase proteins associate with glucose and lipid metabolism in healthy subjects. Diabetes Obes Metab. 2005; 7: 729–736.Heliovaara M. K., Teppo A. M., Karonen S. L., Tuominen J. A., Ebeling P. Plasma IL-6 concentration is inversely related to insulin sensitivity, and acute phase proteins associate with glucose and lipid metabolism in healthy subjects. Diabetes Obes Metab. 2005; 7: 729–736.European Medicines Agency. RoActemra (tocilizumab): summary of product characteristics [online]. Available from URL http://www.ema.europa.eu/docs/en_GB/document_library/EPAREuropean Medicines Agency. RoActemra (tocilizumab): summary of product characteristics [online]. Available at: http://www. ema.europa.eu/docs/en_GB/document_library/EPARChugai Pharmactutical Co. Actemra, a humanized antihuman IL-6 receptor monoclonal antibody obtained approval for indications of rheumatoid arthritis, polyarticular-course juvenile idiopathic arthritis and systemic-onset juvenile idiopathic arthritis [media release]. Available from URL: http://www.chugai-pharm.co.jp/hc/ss/english/index.htmlChugai Pharmactutical Co. Actemra, a humanized antihuman IL-6 receptor monoclonal antibody obtained approval for indications of rheumatoid arthritis, polyarticular-course juvenile idiopathic arthritis and systemic-onset juvenile idiopathic arthritis [media release]. Available at: http://www.chugai-pharm.co.jp/hc/ss/english/index.htmlImagawa T., Ozawa R., Miyamae T. et al. Efficacy and safety in 48-week treatment of tocilizumab in children with polyaticular course JIA with polyarticlar or olygoarticular onset. Ann Rheum Dis. 2007; 66 (Suppl. II): 550.Imagawa T., Ozawa R., Miyamae T. et al. Efficacy and safety in 48-week treatment of tocilizumab in children with polyaticular course JIA with polyarticlar or olygoarticular onset. Ann. Rheum. Dis. 2007; 66 (Suppl. II): 550.Yokota S., Imagawa T., Miyamae T. Safety and efficacy of up to three years of continuous tocilizumab therapy in children with systemic-onset juvenile idiopathic arthritis [SAT0536]. Ann Rheum Dis. 2009; 68 (Suppl. 3): 715.Yokota S., Imagawa T., Miyamae T. Safety and efficacy of up to three years of continuous tocilizumab therapy in children with systemic-onset juvenile idiopathic arthritis [SAT0536]. Ann. Rheum. Dis. 2009; 68 (Suppl. 3): 715.Inaba Y., Aoki C., Ozawa R. Radiologic evaluation of large joints during tocilizumab treatment in children with systemic juvenile idiopathic arthritis [SAT0555]. Ann Rheum Dis. 2009; 68 (Suppl. 3): 720.Inaba Y., Aoki C., Ozawa R. Radiologic evaluation of large joints during tocilizumab treatment in children with systemic juvenile idiopathic arthritis [SAT0555]. Ann. Rheum. Dis. 2009; 68 (Suppl. 3): 720.Yokota S., Imagawa T., Mori M. et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomized, double-blind, placebo-controlled, withdrawal phase III trial. Lancet. 2008; 371: 998–1006.Yokota S., Imagawa T., Mori M. et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomized, double-blind, placebo-controlled, withdrawal phase III trial. Lancet. 2008; 371: 998–1006.Quartier P., Maire D., Souabni L. Efficacy and safety of tocilizumab in systemic onset juvenile idiopathic arthritis in french centers [FRI0462]. Ann Rheum Dis. 2009; 68 (Suppl. 3): 506.Quartier P., Maire D., Souabni L. Efficacy and safety of tocilizumab in systemic onset juvenile idiopathic arthritis in French centers [FRI0462]. Ann. Rheum. Dis. 2009; 68 (Suppl. 3): 506.Kaneko U., Imagawa T., Kishi T. Discrepancy between progression of joint damage and improvement of systemic inflammation in patients with systemic-onset juvenile idiopathic arthritis treated with tocilizumab [SAT0548]. Ann Rheum Dis. 2009; 68 (Suppl. 3): 719.Kaneko U., Imagawa T., Kishi T. Discrepancy between progression of joint damage and improvement of systemic inflammation in patients with systemic-onset juvenile idiopathic arthritis treated with tocilizumab [SAT0548]. Ann. Rheum. Dis. 2009; 68 (Suppl. 3): 719.Баранов А. А., Алексеева Е. И., Денисова Р. В., Валиева С. И., Бзарова Т. М., Исаева К. Б., Слепцова Т. В., Митенко Е. В., Чистякова Е. Г., Фетисова А. Н. Ретроспективный анализ эффективности и безопасности тоцилизумаба у больных тяжелым системным ювенильным идиопатическим артритом: 12 месяцев наблюдения. Вопросы современной педиатрии. 2013; 12 (2): 26–34.Baranov A.A., Alexeeva E.I., Denisova R.V., Valieva S.I., Bzarova T.M., Isaeva K.B., Sleptsova T.V., Mitenko E.V., Chistyakova E.G., Fetisova A.N. Retrospective analysis of tocilizumab efficacy and safety in patients with severe systemic juvenile idiopathic arthritis: 12 months of observation. Voprosy sovremennoi pediatrii = Current pediatrics. 2013; 12 (2): 26–34.

The authors declare that there are no conflicts of interest present.